SAFETY/EFFICACY OF IV ANTI-D FOR TREATMENT OF THROMBOCYTOPENIA IN HCV

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这将是一项前瞻性的先导性研究，研究静脉注射抗D抗体治疗HIV阳性和HIV阴性患者丙型肝炎感染(基于聚乙二醇干扰素的疗法)之前或期间严重的血小板减少症的安全性和有效性。 假设：静脉注射抗-D将使血小板计数增加到建议开始聚乙二醇干扰素治疗的阈值50,000/uL以上。静脉注射抗D抗体将使血小板计数超过建议的50,000个/ul的阈值，以减少聚乙二醇干扰素治疗的剂量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This will be a prospective pilot study of the safety and efficacy of intravenous Anti-D for the treatment of significant thrombocytopenia prior to or during the treatment of hepatitis C infection (with peginterferon-based therapy) in HIV-positive and HIV-negative patients. Hypothesis: Intravenous anti-D will increase platelet counts above the threshold of 50,000/uL recommended for the initiation of peginterferon therapy. Intravenous Anti-D will increase platelet counts above the threshold of 50,000/uL recommended for the dose reduction of peginterferon therapy.